SCHEMBL3986028

SCHEMBL3986028

CC(C)(C)OC(=O)NC(C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1)C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 9/20 0.61
TOP2B Q02880 9/20 0.61
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 2/20 0.40
POLB P06746 2/20 0.40
KDM1A O60341 1/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
RAD52 P43351 1/20 0.40
RECQL P46063 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981536 0.90 TOP2A (0.61) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL3980928 0.90 TOP2A (0.62) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL8104139 0.90 TOP2A (0.60) TOP2ATOP2BKMT2AKDM4EPOLB
SCHEMBL3986033 0.88 TOP2A (0.60) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL3980219 0.88 TOP2A (0.60) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL8484621 0.88 TOP2A (0.78) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL3980933 0.86 TOP2A (0.58) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL3987573 0.85 TOP2A (0.56) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL7234697 0.82 TOP2A (0.65) TOP2ATOP2BKMT2AMEN1NPC1
SCHEMBL3984146 0.81 TOP2A (0.52) TOP2ATOP2BKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1380574-B1 9-aminoacridine derivates and process for the preparation thereof SAMJIN PHARM CO LTD (KR) 2009-05-20 EP disclosed
EP-1380574-A1 9-aminoacridine derivates and process for the preparation thereof Samjin Pharmaceutical Co., Ltd. (KR) 2004-01-14 EP disclosed
US-6620936-B2 Antitumor agents, topoisomerase inhibitors, notoxic SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-16 US disclosed
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 TOP2A 1105/4885TOP2B 841/4885KMT2A 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.